Short Interest in Astrana Health, Inc. (NASDAQ:ASTH) Declines By 12.8%

Astrana Health, Inc. (NASDAQ:ASTH) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,900,000 shares, a drop of 12.8% from the October 15th total of 2,180,000 shares. Based on an average daily volume of 269,800 shares, the short-interest ratio is presently 7.0 days. Currently, 5.2% of the company’s stock are short sold.

Astrana Health Trading Down 2.6 %

ASTH opened at $40.81 on Friday. The company has a quick ratio of 1.84, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 52 week low of $32.04 and a 52 week high of $63.20. The business’s 50 day moving average is $55.04 and its two-hundred day moving average is $47.66. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 1.96 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the company posted $0.47 EPS. On average, research analysts predict that Astrana Health will post 1.16 EPS for the current year.

Institutional Investors Weigh In On Astrana Health

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in Astrana Health during the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC acquired a new position in shares of Astrana Health in the third quarter valued at approximately $35,000. KBC Group NV purchased a new stake in shares of Astrana Health during the third quarter worth approximately $70,000. Quarry LP acquired a new stake in shares of Astrana Health during the third quarter worth $77,000. Finally, Quest Partners LLC acquired a new position in Astrana Health in the 3rd quarter valued at $133,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ASTH. BTIG Research upped their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen assumed coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. Stifel Nicolaus lifted their price objective on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Truist Financial upped their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Robert W. Baird raised their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $65.17.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.